secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001437749-22-026356
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart Q3 net loss $29.3M; cash $114.8M; clinical milestones set for 2023
-------------------------------------------------------------------------

- Net loss $29.3M ($0.23 EPS) vs $17.6M ($0.14) Q3 2021; R&D spend rose 81% to $22.5M.
- Cash & securities $114.8M at Sep 30, down from $131.5M at Jun 30; ops used $14.6M.
- Phase II COVID-19 vaccine showed mucosal IgA and cross-reactivity to Omicron; UK challenge trial set for 2H 2023.
- Norovirus Phase Ib in elderly (55-80) showed dose-dependent IgA; Phase II challenge data expected Q1/Q2 2023.
- Added Ray Stapleton as CTO and Elaine Heron & Mark Watson to board in August 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774922026356/0001437749-22-026356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774922026356/vxrt20221014_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-026356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer